Bind Lands Nanoparticle Development Deal With Pfizer
This article was originally published in The Pink Sheet Daily
Executive Summary
The nanoparticle biotech has signed an agreement with Pfizer to develop an undisclosed number of small molecules that will use the Accurins technology to make the particles easier to use in hard to treat diseases.